Aprea Therapeutics, Inc. reports developments as a clinical-stage precision medicine oncology company developing targeted therapies for patients with biomarker-defined cancers. Its updates center on small-molecule programs designed to exploit cancer-specific genetic vulnerabilities, including APR-1051, an oral WEE1 kinase inhibitor, and ATRN-119, a small-molecule ATR inhibitor, for solid tumor indications.
Recurring news themes include clinical activity from the ACESOT-1051 study of APR-1051, oncology conference presentations, pipeline and corporate updates, financial results, and financing activity supporting research and development. Company communications also describe biomarker-guided development, safety and tolerability observations, and capital actions tied to its clinical-stage oncology strategy.
CatalYm (NASDAQ: APRE) appointed Christian S. Schade as Chairman of the Board effective April 28, 2026.
The company is advancing its lead GDF-15 inhibitor, visugromab, with four late-stage clinical studies ongoing. Mr. Schade brings 30+ years of biotech leadership, most recently leading Halda Therapeutics into a $3.05 billion acquisition in December 2025, and previously served as CEO and chairman of Aprea (2016–2022; chairman 2020–2023).
Aprea Therapeutics (Nasdaq: APRE) announced acceptance of an abstract reporting early results from the first-in-human Phase 1 ACESOT-1051 study of WEE1 inhibitor APR-1051 for advanced solid tumors at the ASCO 2026 Annual Meeting, May 29–June 2, 2026 in Chicago.
The poster presentation (Board 244) is scheduled for May 30, 2026, 1:30 PM–4:30 PM CDT, with presenting author Shiraj Sen, MD, PhD. Trial identifier: ClinicalTrials.gov NCT06260514.
Frazier Life Sciences (APRE) appointed Christian Schade as Senior Advisor, based in its Boston office, to support portfolio companies on corporate strategy and business development.
Schade brings 30+ years of biopharma experience, including CEO roles, prior leadership at Aprea Therapeutics (Nasdaq: APRE), and involvement in multiple acquisitions and an IPO.
Aprea Therapeutics (Nasdaq: APRE) closed an oversubscribed private placement, raising approximately $30 million in gross proceeds on March 31, 2026. The financing included pre-funded warrants to purchase ~37.2 million shares and warrants for ~37.2 million shares with a $0.683 exercise price expiring Dec 31, 2029.
The company said it will use net proceeds for general corporate purposes and R&D to support APR-1051 development, expand the ACESOT-1051 study, and enroll at least 50 patients in uterine serous carcinoma and cyclin E-overexpressing platinum-resistant ovarian cancer cohorts.
Aprea Therapeutics (Nasdaq: APRE) announced an oversubscribed private placement expected to raise approximately $30 million in gross proceeds before fees. The financing includes pre-funded warrants to buy ~37.2 million shares and warrants to purchase an additional ~37.2 million shares with a $0.683 strike.
The company expects to close on or about March 31, 2026, use proceeds for general corporate and R&D purposes, and believes the funds will extend cash runway into Q1 2028. Dose escalation completion for ACESOT-1051 is anticipated in Q2 2027.
Aprea (Nasdaq: APRE) reported a confirmed partial response (PR) to WEE1 inhibitor APR-1051 in the Phase 1 ACESOT-1051 trial at the 220 mg once-daily dose.
The patient with PPP2R1A-mutated endometrial cancer had a 50% reduction in target lesion size at first scan, a further 9.5% reduction at confirmation, and CA-125 fell from 362 U/mL to 40.2 U/mL. To date 24 patients received 10–220 mg; two PRs (one confirmed) and five stable disease responses reported. Dose escalation will progress toward 300 mg once daily in Q2 2026.
Aprea Therapeutics (Nasdaq: APRE) reported Q4 and full-year 2025 results and a corporate update on March 16, 2026. Key clinical progress includes two unconfirmed partial responses to oral WEE1 inhibitor APR-1051 in PPP2R1A-mutated endometrial cancer at 150 mg and 220 mg dose levels with marked CA-125 declines. ATRN-119 RP2D set at 1,100 mg while monotherapy enrollment is paused pending combination studies. Financials: cash of $14.6M (12/31/25), successful private placements raising ~$8.7M, Q4 net loss $2.5M ($0.32/share), 2025 net loss $12.6M ($1.93/share). Company expects cash runway into Q1 2027.
Aprea Therapeutics (Nasdaq: APRE) reported a second unconfirmed partial response in its Phase 1 ACESOT-1051 trial of WEE1 inhibitor APR-1051, observed at the 220 mg dose. The patient had a 50% target lesion reduction and an 87% drop in CA-125, with only Grade 1 adverse events.
To date, 22 patients have been treated across 10–220 mg. Both unconfirmed partial responses occurred in endometrial cancer with PPP2R1A mutations; confirmation and an additional trial update are expected in Q2 2026.
Aprea Therapeutics (Nasdaq: APRE) announced that Oren Gilad, Ph.D., President and CEO, will present a corporate update at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026 at 8:40 am EST. The presentation is virtual and will be webcast.
The webcast will be available for 90 days via the conference link or Aprea's Investors "News & Events" page. Investors may request 1:1 meetings through their Oppenheimer representative.
Aprea Therapeutics (Nasdaq: APRE) expanded its global patent estate in 2025 for its DNA damage response (DDR) oncology programs, with new patents granted in Australia and Japan and multiple pending applications worldwide.
Key points: lead WEE1 inhibitor APR-1051 is in Phase 1 (ACESOT-1051) and ATR inhibitor ATRN-119 is in clinical testing (ABOYA-119); core patents may provide protection into 2045 if pending applications issue.